Our announcements section provides information in relation to the acquisition of Proximagen by Upsher-Smith Laboratories, Inc. in August 2012.
Proximagen's aims to be one of the leading companies developing therapeutics in CNS, inflammation, and oncology.
Proximagen is well suited to be the partner of choice in the area of CNS, inflammation and oncology having in-home expertise and the backing of Upsher-Smith Laboratories, Inc.
read more...
Proximagen is a proud subsidary of Upsher-Smith Laboratories, Inc. More information about our parent company can be found via their website.
